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A B S T R A C T
Objectives: In Singapore, dengue primarily affects adults. This study aimed to determine if older dengue
patients in Singapore have greater morbidity and mortality.
Methods: All laboratory diagnosed dengue patients admitted to Tan Tock Seng Hospital in 2004 were
retrospectively reviewed. Cases were re-classiﬁed into dengue fever and dengue hemorrhagic fever
based on World Health Organization criteria. Demographic, clinical, laboratory, and outcome data of
patients aged 60 years and <60 years were collected.
Results: Of 1971 laboratory conﬁrmed dengue cases, 66 were aged 60 years. Older patients were
signiﬁcantly less likely to be male (44% vs. 64%), and more likely to have diabetes (17% vs. 2%),
hypertension (48% vs. 4%), ischemic heart disease (6% vs. 0.1%), hyperlipidemia (18% vs. 1%), and
secondary dengue infections (64% vs. 34%). Clinical features were similar except older patients were
signiﬁcantly less likely to report fever (92% vs. 99%), or have leukopenia (32% vs. 51%) or
hemoconcentration (0 vs. 5%) on admission. Older patients had similar dengue hemorrhagic fever,
bleeding, hypotension, severe thrombocytopenia, and elevated transaminase rates. Length of hospital
stay, risk of intensive care unit admission, and outcome of death were not statistically different.
Conclusions: Despite greater co-morbidity and secondary dengue infection, older dengue patients in
Singapore did not have greater morbidity or mortality.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.1. Introduction
Dengue is an increasing global health threat with an estimated
2.5 billion people at risk and 50 million new cases annually.1 It is
endemic in over 100 countries in Africa, the Americas, eastern
Mediterranean, Southeast Asia, and Western Paciﬁc. In South and
Southeast Asia, it is endemic in Thailand, Malaysia, Singapore,
Indonesia, Philippines, and Vietnam, while India and Bangladesh
experience cyclical epidemics.2,3
Dengue fever (DF) occurs in children and adults, while dengue
hemorrhagic fever (DHF) predominantly affects children.4 While
adult DHF has been reported in Cuba,5–9 Puerto Rico,10 Singa-
pore,11 Taiwan,12 and Bangladesh,13 the proportion of older adults
is low, comprising 2% >50 years in Cuba,5 7% >60 years in Puerto
Rico,10 and 3% >58 years in Bangladesh.13
However, a disproportionate number of adult dengue deaths
occur in older adults. In Taiwan, ﬁve of eight adult DHF deathswere
in those aged over 60 years.12 In Singapore, 46% (12 of 26) of adult* Corresponding author. Tel.: +65 9792 8896.
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case-fatality and hospitalization rates were highest among young
infants and older adults.8 More recently, a retrospective study in
Puerto Rico showed that older adults had a higher risk for
hospitalization and death compared with youths and adults.17
Current evidence shows that DHF is less common in
adults;4,5,10,13 however older adults account for a signiﬁcant
proportion of adult dengue deaths.12,14–16 The objective of this
studywas to evaluate if older adults with acute dengue infection in
Singapore are at higher risk of DHF and death. We determined the
clinical features and outcome of acute adult dengue infection in
those aged 60 years and compared them with younger adults
(<60 years) in a large retrospective cohort.
2. Methods
We studied all patients admitted to the Department of
Infectious Diseases, Tan Tock Seng Hospital (TTSH), Singapore in
2004, who fulﬁlled the World Health Organization (WHO) criteria
for acute dengue (fever and two or more of: headache, eye pain,
myalgia, arthralgia, leukopenia, rash, and bleeding) and who had
positive dengue laboratory diagnostic tests.11 Probable cases hadses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Number of dengue hemorrhagic fever (DHF) cases per 100 hospitalized
patients with secondary dengue infection for every 10 years in age (p = 0.07).
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Test, Panbio, Queensland, Australia),18 while conﬁrmed cases had
positive PCR assay.19 In Singapore, more than 80% of notiﬁed
dengue cases were hospitalized,15 of which 40% were admitted to
TTSH; the Department of Infectious Diseases managed 94% of
these.
All cases were classiﬁed into DF, DHF, and dengue shock
syndrome (DSS) according toWHO criteria.20 The diagnosis of DHF
required all four criteria of fever, thrombocytopenia, bleeding, and
plasma leakage (hypoproteinemia, 20% change in hematocrit,
pleural effusion, or ascites). A medical chart review was under-
taken to extract demographic, clinical, laboratory, treatment, and
outcome data.
We compared patients aged 60 years with younger adult
patients in terms of demographic data, co-morbidities, clinical
features, laboratory data, treatment, disease severity, and out-
come. To compare the relationship between DHF and age, we
calculated the number of patientswith secondary dengue infection
and DHF for every decade of age to determine the incidence of DHF
per 100 hospitalized secondary dengue infections.
For descriptive analysis, Chi-square and Fisher’s exact tests
were used to compare categorical variables, and the t-test and
Mann–Whitney test to compare continuous variables. All statis-
tical analyses were performed using Stata 9.0 (Stata Corp., College
Station, TX, USA; 2005). All tests were conducted at the 5% level of
signiﬁcance and odds ratios (OR) and corresponding 95%
conﬁdence intervals (CI) were reported where applicable.
3. Results
There were 1971 patients admitted to the Department of
Infectious Diseases, TTSH, Singapore in 2004, of whom 66 were
60 years of age and 1905 were younger. When compared with
younger adults, those who were aged 60 years were signiﬁcantly
more likely to be female (56% vs. 36%, p = 0.001), andmore likely to
have diabetes mellitus (17% vs. 2%, p = 0.0001), hypertension (48%
vs. 4%, p = 0.0001), ischemic heart disease (6% vs. 0.1%, p = 0.0001),
and hyperlipidemia (18% vs. 1%, p = 0.0001). The male preponder-
ance in the younger age group correlated with a higher proportion
of foreigners (39% vs. 9%, p = 0.0001) – in Singapore, foreign
workers are more likely to be male.
Forty-one percent of the older age group and 47% of the younger
age group had conﬁrmed (vs. probable) acute dengue infection (p>
0.05). Among those who had a serological test performed,
signiﬁcantly more secondary dengue infections occurred in those
60 years or older, compared with younger adults (64% vs. 34%,
p = 0.0001).
Figure 1 shows the number of DHF cases per 100 hospitalized
secondary dengue infections for every decade of life. There was a
decreasing trend of incidence of DHF with age in our hospitalized
cohort, although it was not statistically signiﬁcant (p = 0.07 for
trend).
Table 1 shows the detailed comparison of clinical and
laboratory features. Patients 60 years, when compared with
those <60 years, were less likely to report fever (92% vs. 99%,
p = 0.002) and tended to have less rash (38% vs. 50%, p = 0.06).
There was no other difference in clinical symptoms between older
and younger patients, especially for vomiting, diarrhea, and
bleeding. In terms of clinical signs, older and younger patients
had similar rates of hypotension, tachycardia, pleural effusion,
ascites, and hepatomegaly.
With regard to laboratory results, older patients were
signiﬁcantly less likely to have leukopenia (p = 0.002) or hemo-
concentration (p = 0.05) compared with younger patients, and had
similar rates of renal or liver impairment and coagulopathy.In terms of treatment and outcome, older patients were more
likely to be given a platelet transfusion (mostly prophylactic when
platelets dropped below 20  109/l) compared with younger
patients (23% vs. 12%, p = 0.02). Apart from that, they were no
more likely to require intravenous ﬂuid (68% vs. 57%, p = 0.10), be
admitted to the intensive care unit (0 vs. 0.4%, p = 1.00), develop
DHF (2% vs. 6%, p = 0.18), have prolonged hospitalization (4 days vs.
4 days, p = 0.15), or die from acute dengue (0 vs. 0.1%, p = 1.00).
4. Discussion
In contrast to Cuba8 and Puerto Rico,17 where older adults with
dengue were found more likely to die compared with younger
patients, we did not ﬁnd increased adverse clinical outcomes in our
cohort of dengue patients aged 60 years in terms of hypotension,
bleeding, severe hepatic and renal impairment, intensive care unit
admission, prolonged hospitalization, or death, despite a higher
prevalence of medical co-morbidities.
Several studies have found that co-morbidities may contribute
to the severity of dengue. In Cuba, diabetes mellitus,6 asthma,9 and
sickle cell anemia6,9 were found to be risk factors for DHF. In
Taiwan, in addition to age >65 years and prior dengue infection,
diabetes mellitus, hypertension, and chronic renal impairment
were independently associated with DHF and DSS in adults.12 In
Singapore, all of nine adult dengue deaths had co-morbidities, and
diabetes mellitus predominated in 78%.16 In addition, concurrent
bacteremia was more common in older adults with DHF,21 which
may have contributed to the increased risk of death. However, in
our cohort, there was no difference between DF and DHF in terms
of co-morbidities.11
Another possible confounder in reports of increased morbidity
and mortality in the elderly with dengue is the persistence of
dengue antibody.22 A patient may present with and die from
underlying co-morbidities and have detectable dengue antibody
from recent dengue infection within the last 2–3 months. Three of
seven deaths reported from our institution in 200415 and six of
nine deaths reported from another Singapore hospital in 2004 and
200516 were based on positive dengue IgM alone.
In addition, elderly patients may present with acute dengue but
die from exacerbation of underlying co-morbidities or nosocomial
complications. Five of eight adult dengue deaths in Taiwan12 and
two of four conﬁrmed adult dengue deaths (occurring on hospital
days 22 and 33, respectively) reported from our institution15 were
from nosocomial infections, rather than directly from DSS. Lastly,
all studies reporting a preponderance of older adults among adult
dengue deaths12,14–17 may have had selection bias as a result of
Table 1
Demographic, clinical, laboratory, treatment, and outcome data for patients aged 60 years compared with younger patients (<60 years)
Age 60 years (N=66) Age <60 years (N=1905) p-Value
Demographic details
Median age, years 65 (60, 76) 32 (17, 54) <0.001
DHF, n (%) 1 (2) 117 (6) 0.18
Male gender, n (%) 29 (44) 1227 (64) 0.001
Co-morbidity, n (%)
Diabetes mellitus 11 (17) 32 (2) 0.0001
Hypertension 32 (48) 77 (4) 0.0001
Ischemic heart disease 4 (6) 2 (0.1) 0.0001
Hyperlipidemia 12 (18) 20 (1) 0.0001
Singapore citizen, n (%) 60 (91) 1164 (61) 0.0001
Laboratory diagnosis
PCR positive only, n (%) 27 (41) 889 (47) 0.38
Secondary dengue (IgG positive), n (%) 30 out of 47 (64) 428 out of 1260 (34) 0.0001
Clinical features
Fever >38 8C at admission, n (%) 18 (27) 736 (39) 0.07
Median duration of fever from onset, days 5 (2, 7) 5 (3, 7) 0.52
Median duration of fever after admission, days 1 (1, 1) 1 (1, 1) 1.00
Fever, n (%) 61 (92) 1881 (99) 0.002
Headache, n (%) 16 (24) 620 (33) 0.18
Eye pain, n (%) 1 (2) 4 (0.2) 0.16
Myalgia/arthralgia, n (%) 40 (61) 1278 (67) 0.23
Altered mental status, n (%) 0 5 (0.3) 1.00
Rash, n (%) 25 (38) 953 (50) 0.06
Anorexia, n (%) 23 (35) 648 (34) 0.90
Nausea, n (%) 29 (44) 750 (39) 0.52
Vomiting, n (%) 24 (36) 644 (34) 0.69
Abdominal pain, n (%) 10 (15) 270 (14) 0.72
Diarrhea, n (%) 15 (23) 416 (22) 0.88
Sore throat, n (%) 5 (8) 222 (12) 0.43
Cough, n (%) 11 (17) 357 (19) 0.75
Bleeding, n (%)
Nose bleed 0 36 (2) 0.63
Gum bleed 2 (3) 184 (10) 0.08
Period bleed 0 10 (0.5) 1.00
Gastrointestinal bleed 0 3 (0.2) 1.00
Clinical signs
Blood pressure <90 mmHg, n (%) 0 40 (2) 0.64
Pulse >100/min, n (%) 6 (9) 290 (15) 0.22
Abdominal tenderness, n (%) 0 16 (0.8) 0.44
Pleural effusion or ascites, n (%) 0 0 1.00
Hepatomegaly, n (%) 0 1 (0.1) 1.00
Splenomegaly, n (%) 0 0 1.00
Laboratory results
Leukopenia <3.3109/l, n (%) on admission 21 (32) 980 (51) 0.002
Hematocrit >50%, n (%) 0 103 (5) 0.05
Platelet count <50109/l, n (%) 12 (18) 318 (17) 0.74
Median serum creatinine, mmol/l 78 (52, 122) 74 (48, 107) 0.19
Median aspartate transaminase, IU/l 101 (35, 367) 109 (33.5, 550) 0.36
Median alanine transaminase, IU/l 69 (21.5, 299) 73 (20, 399) 0.68
Raised PT, n (%) 2 (3) 192 (10) 0.06
Raised APTT, n (%) 19 (29) 753 (40) 0.09
Management and outcome
Intravenous ﬂuid, n (%) 45 (68) 1091 (57) 0.10
Platelet transfusion, n (%) 15 (23) 230 (12) 0.02
Median length of hospitalization, days 4 (3, 8) 4 (2, 7) 0.15
Intensive care unit admission, n (%) 0 7 (0.4) 1.00
Death, n (%) 0 1 (0.1) 1.00
DHF, dengue hemorrhagic fever; PT, prothrombin time; APTT, activated partial thromboplastin time.
For dichotomous variables, the number of positive cases is shown with percentages in parenthesis; for continuous variables, median values are shown with 5th and 95th
percentiles in parenthesis.
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in this area should examine infection-related mortality.
Of interest, despite a greater proportion of older adults with
secondary dengue infection, we did not ﬁnd increased DHF in our
hospitalized cohort, consistent with a population study in Cuba.8
This may be due to the higher threshold for shock in adults
compared with children because of a lower tendency to increased
capillary permeability.23 The risk of DHF for secondary dengue
infection in our hospitalized cohort was 11% for adults up to age 30years, and 5–7% for adults >30 years up to 60 years. This is
substantially higher than 0.5–0.6% in Havana, Cuba.8 This is likely
due to the case-ﬁnding bias in our study, which reported only
hospitalized patients, in contrast to the population-based study in
Cuba.8
Another possible reason we did not observe highmorbidity and
mortality among our older adultsmay be due to their exposure and
immunity to multiple prior dengue infections, with increased
childhood dengue and DHF before successful vector control in the
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Rico,8,17 and would account for the ﬁnding of an overall small
number of older adults with dengue as well as severe dengue,
compared to adults exposed primarily after 1970, who may not
have immunity tomultiple dengue types. To prove this hypothesis,
a separate study should be performed to determine the dengue
neutralizing antibodies among the general older adult population
in Singapore.
We noted that older adults were more likely to receive a
platelet transfusion despite not having an increased risk of
clinical bleeding or a lower platelet count. In a separate study, we
found that prophylactic platelet transfusions did not reduce
subsequent clinical bleeding in the same cohort. Of note, there
was a signiﬁcantly lower platelet increment the next day and
slower platelet recovery in transfused versus untransfused
patients.
Limitations of the study include the retrospective design of our
study does not permit us to determine attributable morbidity and
mortality. The study also had a relatively small number of older
adults with dengue (3.3%). Another limitation was the use of the
Dengue Duo IgM & IgG Rapid Strip Test, which is not conﬁrmatory
for dengue but is practical and cost-effective in a clinical
laboratory. This rapid diagnostic test was found to be the most
accurate in Asian patients among eight rapid commercial
immunochromatographic assays,25 and ameta-analysis concluded
that while its sensitivity for differentiating primary and secondary
dengue infection was 66–71%, its speciﬁcity, diagnostic odds ratio,
and positive likelihood ratio made it an acceptable test for this
purpose.26 Although patients at TTSH come from all parts of
Singapore, theymay not represent the entire population, especially
those who are in private hospitals.
A recent study in Singapore found that increased age was
signiﬁcantly associated with fatigue following dengue infection.27
Our study, however, was not able to examine this due to the
retrospective study design, for which there was no long-term
follow-up information. The strength of our study is the detailed
serial clinical and laboratory data collection, which allowed more
accurate classiﬁcation of DF and DHF with serial data from the
entire course of illness.
In conclusion, despite the observations in other ecological
settings of increased risk of hospitalization and death in older
adults with dengue,8,17 and the disproportionate prevalence of
older adults among reported adult dengue deaths,12,14–17 we did
not ﬁnd increased morbidity and mortality in our hospitalized
cohort of adult dengue in Singapore for reasons that have been
discussed and remain to be explored.
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